• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of bariatric surgery on long-term cardiovascular outcomes: a systematic review and meta-analysis of population-based cohort studies
Surg Obes Relat Dis. 2022 May 16:S1550-7289(22)00202-7. doi: 10.1016/j.soard.2022.05.007. Online ahead of print.ABSTRACTThis meta-analysis aimed to compare the effects of bariatric surgery and nonsurgery on cardiovascular outcomes in patients with obesity. A systematic literature search of the Medline (via PubMed), Embase, and Cochrane Central Register of Controlled Trials databases was performed until August 18th, 2021. Population-based cohort studies comparing long-term cardiovascular outcomes for patients with obesity undergoing bariatric surgery or not were included. A meta-analysis of relative risks (RRs) was performe...
Source: Surgery for Obesity and Related Diseases : official journal of the American Society for Bariatric Surgery - June 18, 2022 Category: Surgery Authors: Borui Tang Yi Zhang Yifan Wang Xinrui Wang Zhuoling An Xiaojia Yu Source Type: research

Bariatric surgery and diabetes remission: how far have we progressed?
This article will review the effectiveness of bariatric procedures on the remission and improvement of diabetes and its implicated mechanisms. PMID: 30298760 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - October 12, 2018 Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

What Are Endoscopic Bariatric Therapies?
The high prevalence of overweight and obesity in the United States negatively affects the health of the population. Obesity increases the risk of various diseases, including diabetes mellitus, hypertension, coronary heart disease, sleep apnea, stroke, gatroesophageal reflux disease, gall bladder disease, certain types of malignancy, and non-alcoholic fatty liver diseases.1,2 Reducing obesity in the United States has become a public health priority.1,2 Current approaches to therapeutic weight loss include dietary approaches, lifestyle intervention, pharmacology, and surgery.
Source: Journal of the American Dietetic Association - January 25, 2017 Category: Nutrition Authors: Wendy Marcason Tags: From the Academy Source Type: research

New devices for the bariatric patient.
Authors: Isabelle D, Christophe S, Bruno D Abstract Over the past years, the global prevalence of obesity has risen dramatically. This generates enormous costs for the health care system, since obesity is associated with hypertension, diabetes mellitus type 2, coronary heart diseases, stroke, dyslipidemia, psychological problems, and cancer. Bariatric surgery has demonstrated to be the most effective and durable treatment option in the morbidly obese patient. Despite its evidence based efficacy, less than 1% of obese patients will undergo surgery. The role of new, less-invasive devices for the bariatric patient nee...
Source: Minerva Chirurgica - March 2, 2016 Category: Surgery Tags: Minerva Chir Source Type: research

Bariatric Surgery in the United Kingdom: A Cohort Study of Weight Loss and Clinical Outcomes in Routine Clinical Care
Conclusions Bariatric surgery as delivered in the UK healthcare system is associated with dramatic weight loss, sustained at least 4 y after surgery. This weight loss is accompanied by substantial improvements in pre-existing T2DM and hypertension, as well as a reduced risk of incident T2DM, hypertension, angina, MI, and obstructive sleep apnoea. Widening the availability of bariatric surgery could lead to substantial health benefits for many people who are morbidly obese.
Source: PLoS Medicine - December 22, 2015 Category: Internal Medicine Authors: Ian J. Douglas et al. Source Type: research

Bariatric Surgery: "Roux"-minating on Endothelial Cell and HDL Function.
Abstract Obesity, defined as a body mass index ≥ 30 kg/m2, is pandemic. Though prevalence in the United States has plateaued at ~31% of adults (78 million), worldwide obesity rates continue to rise(1). Perhaps more concerning is the high level of childhood obesity: 16.9% in US and ~13% (and rising) in developing countries(2). Why the alarm? Longitudinal studies of overweight or obese individuals have identified a 20 fold increase in risk for developing diabetes mellitus type 2 (T2D) and 1.5 fold increase risk for cardiovascular disease (CVD), including myocardial infarction, stroke and heart failure(3, 4). As ob...
Source: Circulation - February 11, 2015 Category: Cardiology Authors: Brown JD Tags: Circulation Source Type: research

DiaSurg 2 trial - surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial - DRKS00004550
This study aims at investigating whether Roux-en-Y gastric bypass (RYGB) is an efficient treatment for non-severely obese T2DM patients in terms of preventing long-term complications and mortality. Methods: The DiaSurg 2 trial is a multicenter, open randomized controlled trial comparing RYGB including standardized medical treatment if needed to exclusive standardized medical treatment of T2DM (control group). The primary endpoint is a composite time-to-event endpoint (cardiovascular death, myocardial infarction, coronary bypass, percutaneous coronary intervention, non-fatal stroke, amputation, surgery for peripheral athero...
Source: Trials - June 20, 2013 Category: Journals (General) Authors: Hannes KenngottGabriella ClemensMatthias GondanJonas SenftMarkus DienerGottfried RudofskyPeter NawrothMarkus BüchlerLars FischerBeat Müller-Stich Source Type: research

DiaSurg 2 trial - surgical vs. medical treatment of insulin-dependent type 2 diabetes mellitus in patients with a body mass index between 26 and 35 kg/m2: study protocol of a randomized controlled multicenter trial - DRKS00004550
This study aims at investigating whether Roux-en-Y gastric bypass (RYGB) is an efficient treatment for non-severely obese T2DM patients in terms of preventing long-term complications and mortality. Methods: The DiaSurg 2 trial is a multicenter, open randomized controlled trial comparing RYGB including standardized medical treatment if needed to exclusive standardized medical treatment of T2DM (control group). The primary endpoint is a composite time-to-event endpoint (cardiovascular death, myocardial infarction, coronary bypass, percutaneous coronary intervention, non-fatal stroke, amputation, surgery for peripheral athero...
Source: BioMed Central - June 20, 2013 Category: Journals (General) Authors: Hannes G KenngottGabriella ClemensMatthias GondanJonas SenftMarkus K DienerGottfried RudofskyPeter P NawrothMarkus W BüchlerLars FischerBeat P Müller-Stich Source Type: research

Bariatric Surgery Is Associated with a Reduction in Major Macrovascular and Microvascular Complications in Moderately to Severely Obese Patients with Type 2 Diabetes Mellitus
Background: Bariatric surgery (BAR) has been established as an effective treatment for type 2 diabetes mellitus (T2DM) in obese patients. However, few studies have examined the mid- to long-term outcomes of bariatric surgery in diabetic populations. Specifically, no comparative studies have broadly examined major macrovascular and microvascular complications in bariatric surgical patients vs similar, nonbariatric surgery controls.Study Design: We conducted a large, population-based, retrospective cohort study of adult obese patients with T2DM, from 1996 to 2009, using UB-04 administrative data and vital records. Eligible p...
Source: Journal of the American College of Surgeons - February 6, 2013 Category: Surgery Authors: Brent L. Johnson, Dawn W. Blackhurst, Bruce B. Latham, David L. Cull, Eric S. Bour, Thomas L. Oliver, Bradley Williams, Spence M. Taylor, John D. Scott Tags: Southern Surgical Association Articles Source Type: research